AN2 Therapeutics grants inducement equity to new CMO
AN2 Therapeutics granted stock options for 233,333 shares at $5.36 and 116,667 RSUs to newly appointed CMO Cameron Trenor, M.D., vesting over four years under Nasdaq Rule 5635(c)(4).
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.